Sino Biopharmaceutical (HKG:1177) submitted a new indication application to Chinese medical products regulators for its anlotinib hydrochloride capsule combination with penpulimab injection for hepatocellular carcinoma or liver cancer.
The application comes after Sino Biopharm completed its interim analysis of its phase 3 clinical study for the drug combination, according to a Thursday filing with the Hong Kong Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments